Reuters logo
BRIEF-Cytokinetics starts phase 3 clinical trial of omecamtiv mecarbil
December 1, 2016 / 12:55 PM / a year ago

BRIEF-Cytokinetics starts phase 3 clinical trial of omecamtiv mecarbil

Dec 1 (Reuters) - Cytokinetics Inc:

* Cytokinetics announces start of galactic-hf, a phase 3 clinical trial of omecamtiv mecarbil

* Coincident with start of trial, Amgen will make a $26.7 million milestone payment to CytoKinetics

* Cytokinetics - galactic-hf will be conducted under a special protocol assessment (spa) with U.S. FDA Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below